Overview

Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A open label non- randomized Phase II trial. It is anticipated that approximately 46 patients will be treated. STUDY OBJECTIVES Primary: Objective response rate Secondary: Progression free survival, Overall survival and Safety of Tarceva
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Gallego de Cancer de Pulmon
Treatments:
Erlotinib Hydrochloride